James T. Becker

James T. Becker

Auto-generated profile, based on publicly available information

James T. Becker

University of Pittsburgh, Pittsburgh, PA USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBrian W. Kunkle
Brian W. Kunkle
T(The European Alzheimer’s Disease Initiative (Eadi)
The European Alzheimer’s Disease Initiative (Eadi)
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
RSRebecca Sims
Rebecca Sims
JBJoshua C. Bis
Joshua C. Bis
MPMargaret A. Pericak-Vance
Margaret A. Pericak-Vance

6 August 2009 in Human Brain Mapping
Verified
Journal Article
Open access
PDF file
CRCyrus A. Raji
Cyrus A. Raji
AHApril J. Ho
April J. Ho
NPNeelroop N. Parikshak
Neelroop N. Parikshak
JBJames T. Becker
James T. Becker
OLOscar L. Lopez
Oscar L. Lopez
PTPaul M. Thompson
Paul M. Thompson
Obesity is associated with increased risk for cardiovascular health problems including diabetes, hypertension, and stroke. These cardiovascular afflictions increase risk for cognitive decline and dementia, but it is unknown whether these factors, specifically obesity and Type II diabetes, are associated with specific patterns of brain atrophy. We used tensor‐based morphometry (TBM) to examine gray matter (GM) and white matter (WM) volume differences in 94 elderly subjects who remained cognitively normal for at least 5 years after their scan. Bivariate analyses with corrections for multiple comparisons strongly linked body mass index (BMI), fasting plasma insulin (FPI) levels, and Type II Diabetes Mellitus (DM2) with atrophy in frontal, temporal, and subcortical brain regions. A multiple regression model, also correcting for multiple comparisons, revealed that BMI was still negatively correlated with brain atrophy (FDR 30) showed atrophy in the frontal lobes, anterior cingulate gyrus, hippocampus, and thalamus compared with individuals with a normal BMI (18.5–25). Overweight subjects (BMI: 25–30) had atrophy in the basal ganglia and corona radiata of the WM. Overall brain volume did not differ between overweight and obese persons. Higher BMI was associated with lower brain volumes in overweight and obese elderly subjects. Obesity is therefore associated with detectable brain volume deficits in cognitively normal elderly subjects. Hum Brain Mapp, 2010.

1 June 2004 in Archives of General Psychiatry
Verified
Journal Article
Closed access
PDF file
MBMeryl A. Butters
Meryl A. Butters
EWEllen M. Whyte
Ellen M. Whyte
RNRobert D. Nebes
Robert D. Nebes
ABAmy E. Begley
Amy E. Begley
MDMary Amanda Dew
Mary Amanda Dew
JBJames T. Becker
James T. Becker
Research from JAMA Psychiatry — The Nature and Determinants of Neuropsychological Functioning in Late-LifeDepression

1 October 2003 in Archives of Neurology
Verified
Journal Article
Closed access
OLOscar L. Lopez
Oscar L. Lopez
WJWilliam J. Jagust
William J. Jagust
SDSteven Trent DeKosky
Steven Trent DeKosky
JBJames T. Becker
James T. Becker
AFAnnette Fitzpatrick
Annette Fitzpatrick
LKLewis H. Kuller
Lewis H. Kuller
To examine the prevalence of mild cognitive impairment (MCI) and its diagnostic classification in the Cardiovascular Health Study (CHS) Cognition Study. The CHS Cognition Study is an ancillary study of the CHS that was conducted to determine the presence of MCI and dementia in the CHS cohort. Multicenter population study. We examined 3608 participants in the CHS who had undergone detailed neurological, neuropsychological, neuroradiological, and psychiatric testing to identify dementia and MCI. The prevalence of MCI was determined for the whole cohort, and specific subtypes of MCI were examined in detail only at the Pittsburgh, Pa, center (n = 927). Mild cognitive impairment was classified as either MCI amnestic-type or MCI multiple cognitive deficits-type. The overall prevalence of MCI was 19% (465 of 2470 participants); prevalence increased with age from 19% in participants younger than 75 years to 29% in those older than 85 years. The overall prevalence of MCI at the Pittsburgh center was 22% (130 of 599 participants); prevalence of the MCI amnesic-type was 6% and of the MCI multiple cognitive deficits-type was 16%. Twenty-two percent of the participants aged 75 years or older had MCI. Mild cognitive impairment is a heterogeneous syndrome, where the MCI amnestic-type is less frequent than the MCI multiple cognitive deficits-type. Most of the participants with MCI had comorbid conditions that may affect their cognitive functions.

29 March 2012 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
ZDZari Dastani
Zari Dastani
MHMarie-France Hivert
Marie-France Hivert
NTNicholas Timpson
Nicholas Timpson
JPJohn R. B. Perry
John R. B. Perry
XYXin Yuan
Xin Yuan
JRJ. Brent Richards
J. Brent Richards
Circulating levels of adiponectin, a hormone produced predominantly by adipocytes, are highly heritable and are inversely associated with type 2 diabetes mellitus (T2D) and other metabolic traits. We conducted a meta-analysis of genome-wide association studies in 39,883 individuals of European ancestry to identify genes associated with metabolic disease. We identified 8 novel loci associated with adiponectin levels and confirmed 2 previously reported loci (P = 4.5×10−8–1.2×10−43). Using a novel method to combine data across ethnicities (N = 4,232 African Americans, N = 1,776 Asians, and N = 29,347 Europeans), we identified two additional novel loci. Expression analyses of 436 human adipocyte samples revealed that mRNA levels of 18 genes at candidate regions were associated with adiponectin concentrations after accounting for multiple testing (p<3×10−4). We next developed a multi-SNP genotypic risk score to test the association of adiponectin decreasing risk alleles on metabolic traits and diseases using consortia-level meta-analytic data. This risk score was associated with increased risk of T2D (p = 4.3×10−3, n = 22,044), increased triglycerides (p = 2.6×10−14, n = 93,440), increased waist-to-hip ratio (p = 1.8×10−5, n = 77,167), increased glucose two hours post oral glucose tolerance testing (p = 4.4×10−3, n = 15,234), increased fasting insulin (p = 0.015, n = 48,238), but with lower in HDL-cholesterol concentrations (p = 4.5×10−13, n = 96,748) and decreased BMI (p = 1.4×10−4, n = 121,335). These findings identify novel genetic determinants of adiponectin levels, which, taken together, influence risk of T2D and markers of insulin resistance. Serum adiponectin levels are highly heritable and are inversely correlated with the risk of type 2 diabetes (T2D), coronary artery disease, stroke, and several metabolic traits. To identify common genetic variants associated with adiponectin levels and risk of T2D and metabolic traits, we conducted a meta-analysis of genome-wide association studies of 45,891 multi-ethnic individuals. In addition to confirming that variants at the ADIPOQ and CDH13 loci influence adiponectin levels, our analyses revealed that 10 new loci also affecting circulating adiponectin levels. We demonstrated that expression levels of several genes in these candidate regions are associated with serum adiponectin levels. Using a powerful novel method to assess the contribution of the identified variants with other traits using summary-level results from large-scale GWAS consortia, we provide evidence that the risk alleles for adiponectin are associated with deleterious changes in T2D risk and metabolic syndrome traits (triglycerides, HDL, post-prandial glucose, insulin, and waist-to-hip ratio), demonstrating that the identified loci, taken together, impact upon metabolic disease.

1 October 2003 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
OLOscar L. Lopez
Oscar L. Lopez
WJWilliam J. Jagust
William J. Jagust
CDCorinne Dulberg
Corinne Dulberg
JBJames T. Becker
James T. Becker
SDSteven Trent DeKosky
Steven Trent DeKosky
LKLewis H. Kuller
Lewis H. Kuller
OLDER PARTICIPANTS with mild cognitive impairment (MCI) have an increased risk of developing dementia, especially Alzheimer disease.1 Therefore, the proper identification of these individuals is important because they constitute a clinical entity that is suitable for therapeutic interventions. However, one of the problems in identifying risk factors for MCI is that there are several neurological, systemic, and psychiatric syndromes that can cause cognitive impairment. Elderly subjects who have cerebrovascular disease,2 white matter lesions (WMLs),3 diabetes mellitus,4 and hypertension and heart disease,5 or depression6 can present with mild cognitive deficits. Furthermore, studies that focused only on risk factors for MCI have found that hypertension diagnosed in midlife7 and a history of coronary artery bypass grafting8 increased the risk of developing MCI. In this study, we examined the risk factors for MCI in the context of a longitudinal population study, the Cardiovascular Health Study (CHS) Cognition Study. These factors were first examined for the whole CHS cohort, and further analysis was conducted in the Pitts burgh, Pa, sample, where we examined the association between risk factors and MCI subgroups.